NO329816B1 - Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning - Google Patents
Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning Download PDFInfo
- Publication number
- NO329816B1 NO329816B1 NO20023266A NO20023266A NO329816B1 NO 329816 B1 NO329816 B1 NO 329816B1 NO 20023266 A NO20023266 A NO 20023266A NO 20023266 A NO20023266 A NO 20023266A NO 329816 B1 NO329816 B1 NO 329816B1
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- human
- ser
- antibody
- binding
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 4
- -1 their use Proteins 0.000 title description 2
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 title 1
- 102000052620 human IL10 Human genes 0.000 title 1
- 238000009739 binding Methods 0.000 claims description 91
- 230000027455 binding Effects 0.000 claims description 90
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 108010002352 Interleukin-1 Proteins 0.000 claims description 34
- 102000000589 Interleukin-1 Human genes 0.000 claims description 34
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 33
- 108020004705 Codon Proteins 0.000 claims description 30
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 15
- 206010003246 arthritis Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 9
- 206010040070 Septic Shock Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 230000001363 autoimmune Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 206010065687 Bone loss Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010014824 Endotoxic shock Diseases 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010027654 Allergic conditions Diseases 0.000 claims description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 230000004097 bone metabolism Effects 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000004768 organ dysfunction Effects 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 206010035653 pneumoconiosis Diseases 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 230000009429 distress Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000000890 antigenic effect Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 208000037765 diseases and disorders Diseases 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 5
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 229940115586 simulect Drugs 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 229960004669 basiliximab Drugs 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 101001033289 Macaca fascicularis Interleukin-1 beta Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102100036865 Solute carrier family 52, riboflavin transporter, member 3 Human genes 0.000 description 1
- 101710102466 Solute carrier family 52, riboflavin transporter, member 3 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 101150076615 ck gene Proteins 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 102000050164 human Col8A1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000018276 interleukin-1 production Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0001448.0A GB0001448D0 (en) | 2000-01-21 | 2000-01-21 | Organic compounds |
| PCT/EP2001/000591 WO2001053353A2 (en) | 2000-01-21 | 2001-01-19 | Recombinant antibodies to human interkleukin-1 beta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023266D0 NO20023266D0 (no) | 2002-07-05 |
| NO20023266L NO20023266L (no) | 2002-08-28 |
| NO329816B1 true NO329816B1 (no) | 2010-12-27 |
Family
ID=9884137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023266A NO329816B1 (no) | 2000-01-21 | 2002-07-05 | Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US20030124617A1 (ja) |
| EP (1) | EP1248804B2 (ja) |
| JP (2) | JP3978338B2 (ja) |
| KR (1) | KR100697126B1 (ja) |
| CN (1) | CN1395581B (ja) |
| AR (1) | AR027253A1 (ja) |
| AT (1) | ATE346868T1 (ja) |
| AU (1) | AU772949B2 (ja) |
| BR (1) | BR0107661A (ja) |
| CA (1) | CA2396212C (ja) |
| CO (1) | CO5261584A1 (ja) |
| CY (1) | CY1107989T1 (ja) |
| CZ (1) | CZ302738B6 (ja) |
| DE (1) | DE60124863T3 (ja) |
| DK (1) | DK1248804T4 (ja) |
| ES (1) | ES2274865T5 (ja) |
| GB (1) | GB0001448D0 (ja) |
| HK (1) | HK1050013A1 (ja) |
| HU (1) | HUP0204156A3 (ja) |
| IL (2) | IL150551A0 (ja) |
| MX (1) | MXPA02007091A (ja) |
| MY (1) | MY155269A (ja) |
| NO (1) | NO329816B1 (ja) |
| NZ (1) | NZ519936A (ja) |
| PE (1) | PE20011219A1 (ja) |
| PL (1) | PL207642B1 (ja) |
| PT (1) | PT1248804E (ja) |
| RU (1) | RU2264413C2 (ja) |
| SI (1) | SI1248804T2 (ja) |
| SK (1) | SK288054B6 (ja) |
| TR (1) | TR200201780T2 (ja) |
| WO (1) | WO2001053353A2 (ja) |
| ZA (1) | ZA200205659B (ja) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| SK1152003A3 (en) | 2000-06-29 | 2003-07-01 | Abbott Lab | Dual specificity antibodies and methods of making and using |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| KR20040077889A (ko) * | 2002-01-28 | 2004-09-07 | 메다렉스, 인코포레이티드 | 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체 |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| WO2005029091A2 (en) * | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
| US7625559B2 (en) * | 2004-02-06 | 2009-12-01 | University Of Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
| AU2006208286A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| PA8672101A1 (es) * | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| JP4931919B2 (ja) * | 2005-06-21 | 2012-05-16 | ゾーマ テクノロジー リミテッド | ＩＬ−１β結合抗体およびその断片 |
| CN101291693B (zh) * | 2005-10-26 | 2012-10-03 | 诺瓦提斯公司 | IL-1β化合物的新用途 |
| DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| EP2021026A1 (en) * | 2006-04-14 | 2009-02-11 | Novartis AG | Use of il-i antibodies for treating ophthalmic disorders |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| CA2673592C (en) | 2006-12-20 | 2014-03-25 | Xoma Technology Ltd. | Methods for the treatment of il-1.beta. related diseases |
| WO2008082651A2 (en) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Dual-specific il-1a/ il-1b antibodies |
| CN101668531B (zh) | 2007-02-28 | 2014-05-07 | 默沙东公司 | 用于治疗免疫病症的联合治疗 |
| CA3030662C (en) * | 2007-05-29 | 2020-06-30 | Novartis Ag | New indications for anti-il-1-beta therapy |
| WO2009086003A1 (en) * | 2007-12-20 | 2009-07-09 | Xoma Technology Ltd. | Methods for the treatment of gout |
| PL2293816T3 (pl) * | 2008-06-06 | 2013-04-30 | Xoma Us Llc | Sposoby leczenia reumatoidalnego zapalenia stawów |
| WO2010028275A1 (en) | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES |
| US20110117087A1 (en) | 2009-10-26 | 2011-05-19 | Reinhard Franze | Method for the production of a glycosylated immunoglobulin |
| SG2014014724A (en) | 2010-05-07 | 2014-07-30 | Xoma Technology Ltd | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS |
| DE102010033565B4 (de) * | 2010-07-27 | 2012-06-21 | Tetec Tissue Engineering Technologies Ag | Marker zur Bestimmung von Chondrozyten |
| ES2612459T3 (es) | 2010-08-02 | 2017-05-17 | Regeneron Pharmaceuticals, Inc. | Ratones que producen proteínas de unión que comprenden dominios VL |
| US9085621B2 (en) | 2010-09-10 | 2015-07-21 | Apexigen, Inc. | Anti-IL-1β antibodies |
| DK2550363T3 (en) | 2011-02-25 | 2015-03-23 | Regeneron Pharma | ADAM6 mice |
| PT2739740T (pt) | 2011-08-05 | 2020-01-09 | Regeneron Pharma | Cadeia leve universal humanizada de murganhos |
| DE102011083595A1 (de) | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose |
| WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
| SG10201605675WA (en) | 2011-12-20 | 2016-09-29 | Regeneron Pharma | Humanized light chain mice |
| WO2013122544A2 (en) | 2012-02-13 | 2013-08-22 | Agency For Science, Technology And Research | IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES |
| SG10201913429WA (en) | 2012-06-12 | 2020-03-30 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| CA2942697A1 (en) | 2014-03-21 | 2015-09-24 | Lynn Macdonald | Non-human animals that make single domain binding proteins |
| EP3119811B1 (en) | 2014-03-21 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| MX2021005905A (es) | 2018-11-20 | 2021-06-23 | Janssen Biotech Inc | Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23. |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772685A (en) | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| FR2640146B1 (fr) * | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
| US5429614A (en) | 1993-06-30 | 1995-07-04 | Baxter International Inc. | Drug delivery system |
| WO1995001997A1 (en) * | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
-
2000
- 2000-01-21 GB GBGB0001448.0A patent/GB0001448D0/en not_active Ceased
-
2001
- 2001-01-18 MY MYPI20010226A patent/MY155269A/en unknown
- 2001-01-18 CO CO01003434A patent/CO5261584A1/es active IP Right Grant
- 2001-01-19 CA CA2396212A patent/CA2396212C/en not_active Expired - Fee Related
- 2001-01-19 PE PE2001000065A patent/PE20011219A1/es not_active Application Discontinuation
- 2001-01-19 BR BR0107661-2A patent/BR0107661A/pt not_active IP Right Cessation
- 2001-01-19 DK DK01905671.2T patent/DK1248804T4/da active
- 2001-01-19 JP JP2001553825A patent/JP3978338B2/ja not_active Expired - Fee Related
- 2001-01-19 MX MXPA02007091A patent/MXPA02007091A/es active IP Right Grant
- 2001-01-19 SK SK1035-2002A patent/SK288054B6/sk not_active IP Right Cessation
- 2001-01-19 EP EP01905671A patent/EP1248804B2/en not_active Expired - Lifetime
- 2001-01-19 PL PL356297A patent/PL207642B1/pl unknown
- 2001-01-19 CN CN018039529A patent/CN1395581B/zh not_active Expired - Fee Related
- 2001-01-19 AU AU33697/01A patent/AU772949B2/en not_active Ceased
- 2001-01-19 CZ CZ20022531A patent/CZ302738B6/cs not_active IP Right Cessation
- 2001-01-19 RU RU2002121649/13A patent/RU2264413C2/ru not_active IP Right Cessation
- 2001-01-19 SI SI200130698T patent/SI1248804T2/sl unknown
- 2001-01-19 AR ARP010100247A patent/AR027253A1/es active IP Right Grant
- 2001-01-19 PT PT01905671T patent/PT1248804E/pt unknown
- 2001-01-19 AT AT01905671T patent/ATE346868T1/de active
- 2001-01-19 WO PCT/EP2001/000591 patent/WO2001053353A2/en active IP Right Grant
- 2001-01-19 ES ES01905671T patent/ES2274865T5/es not_active Expired - Lifetime
- 2001-01-19 KR KR1020027009374A patent/KR100697126B1/ko not_active IP Right Cessation
- 2001-01-19 HU HU0204156A patent/HUP0204156A3/hu not_active Application Discontinuation
- 2001-01-19 DE DE60124863T patent/DE60124863T3/de not_active Expired - Lifetime
- 2001-01-19 NZ NZ519936A patent/NZ519936A/en not_active IP Right Cessation
- 2001-01-19 TR TR2002/01780T patent/TR200201780T2/xx unknown
- 2001-01-19 IL IL15055101A patent/IL150551A0/xx unknown
- 2001-01-19 US US10/181,324 patent/US20030124617A1/en not_active Abandoned
-
2002
- 2002-07-02 IL IL150551A patent/IL150551A/en not_active IP Right Cessation
- 2002-07-05 NO NO20023266A patent/NO329816B1/no not_active IP Right Cessation
- 2002-07-16 ZA ZA2002/05659A patent/ZA200205659B/en unknown
-
2003
- 2003-03-19 HK HK03102022.5A patent/HK1050013A1/zh unknown
-
2006
- 2006-07-11 US US11/484,472 patent/US7491392B2/en not_active Expired - Fee Related
- 2006-12-29 CY CY20061101860T patent/CY1107989T1/el unknown
-
2007
- 2007-01-04 JP JP2007000148A patent/JP2007097598A/ja active Pending
-
2009
- 2009-01-09 US US12/351,007 patent/US20090232803A1/en not_active Abandoned
-
2011
- 2011-03-10 US US13/044,918 patent/US20110182894A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1248804B2 (en) | Recombinant antibodies to human interleukin-1 beta | |
| AU2001295490B2 (en) | Antibodies to human IL-1beta | |
| EP1299421B1 (en) | Antibodies to human mcp-1 | |
| AU2001295490A1 (en) | Antibodies to human IL-1beta | |
| AU2001283903A1 (en) | Antibodies to human MCP-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |